type="text/javascript">

Epirus plans to be in the first wave of biosimilars for blockbuster drugs

Epirus

Epirus Biopharmaceuticals plans to be in the first wave of biosimilars for blockbuster drugs like Remicade, Humira and Actemra, which had a combined 2013 revenue of approx. $20 billion. “In our view, Epirus’s concentrated disease focus and strategy of regional partnerships should allow it to bring in revenue, mitigate spend and build out its commercial footprint,” said Wedbush analyst Heather Behanna. Further, the analyst notes that patent expirations are expected in the next 5 years for biologic drugs such as antibodies that are estimated to represent $60 billion of revenue annually. This, according to the analysts, “creates an opportunity for biosimilars, lower-cost non-branded biologics.”

Read the source article at StreetInsider.com

About the Author

Leave a Reply

*